DOCSLIB.ORG

A Higher Body Mass Index and Fat Mass Are Factors Predictive of Docetaxel Dose Intensity

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
A Higher Body Mass Index and Fat Mass Are Factors Predictive of Docetaxel Dose Intensity ANTICANCER RESEARCH 33: 5655-5662 (2013) A Higher Body Mass Index and Fat Mass Are Factors Predictive of Docetaxel Dose Intensity SOPHIE GOUÉRANT1,2, MARIANNE LEHEURTEUR1, MAHER CHAKER1, ROMAIN MODZELEWSKI1, OLIVIER RIGAL1, CORINNE VEYRET1, GÉRALDINE LAURIDANT3 and FLORIAN CLATOT1,4 1Department of Oncology, Henri Becquerel Center, Rouen, France; 2Department of Oncology, François Baclesse Center, Caen, France; 3Department of Oncology, Oscar Lambret Center, Lille, France; 4Inserm 918 Unit, Rouen, France Abstract. Background: Few data are published on Nevertheless, these regimens are associated with docetaxel toxicity in obese patients. Patients and Methods: haematological and non-haematological toxicities that remain All obese patients (n=100) treated for early breast cancer unpredictable and which may alter the dose intensity of the during three consecutive years at our Institution, were treatment. Doses of chemotherapy are usually based on the retrospectively investigated. The same number of non-obese body surface area (BSA), mostly calculated with the Dubois patients was randomly selected and used as controls. We formula (3), which considers only weight and size. However, assessed the factors predictive of the relative dose intesity several studies have shown that the use of BSA for reducing (RDI) reduction, including body composition. Results: A the inter-individual variability of pharmacokinetic factors total of 18% (n=18) of obese patients and 5% (n=5) of [clearance, area under curve] is efficient only for a small non-obese patients required reduction of docetaxel RDI due number of chemotherapy agents and not for epirubicin or to toxicity (p=0.008). In a multivariate analysis, body mass docetaxel (4). Other factors may impact on the index (BMI) and age were predictive of a reduction in RDI. pharmacokinetics of drugs, including body composition (fat Among the 89 patients with a determination of body mass, lean body mass) (5), which may predict tolerance to composition, patients with a higher fat mass more chemotherapy (6, 7). In the era of personalised medicine, one frequently had a reduction in docetaxel RDI (p=0.002). In of the main issues is the ability to adjust the dose of multivariate analysis, fat mass was the only independent chemotherapy in cases of obesity. factor predictive of a reduction in docetaxel RDI. The rate of obesity, defined by a BMI greater than 30 kg/m2, Conclusion: Obese patients treated for early breast cancer has been increasing in recent years both in developed and more frequently required a reduction in docetaxel RDI. Fat developing countries. With a prevalence of approximately 20% mass seems to be the best factor predictive of a reduction in in the United States, the United Kingdom and Australia, docetaxel RDI. obesity has reached epidemic proportions in Western countries (8). Regarding breast cancer, obesity is both a risk factor in Breast cancer is a common disease: 1.4 million women were post-menopausal women (9) and an indicator of a poor diagnosed worldwide in 2008 (1). Adjuvant chemotherapy prognosis (10). Even if increasing numbers of obese patients based on regimens using anthracyclines (doxorubicin, are treated for breast cancer, few data exist on the adaptation epirubicin) and taxanes (paclitaxel, docetaxel) has significantly of doses of chemotherapy for this sub-population. In daily improved survival for women with early breast cancer (2). practice, some physicians reduce doses for obese patients These regimens are highly codified, and the dose intensity, is because of a fear of excessive toxicity (11), but without actual crucial for efficacy. evidence-based data. Recently, the American Society of Clinical Oncology (ASCO) published guidelines on the adaption of chemotherapy doses for obese patients (12). The recommendation is not to reduce chemotherapy doses for obese Correspondence to: Sophie Gouérant, Avenue General Harris 14000 patients because of the lack of evidence of increased toxicity Caen, France. Tel: +33 620142126, Fax: +33 231455050, e-mail: [email protected] in this population and the risk of reducing the efficacy of the treatment. Nevertheless, among the studies that contributed to Key Words: Early breast cancer, docetaxel, obesity, fat mass, dose these recommendations, none included chemotherapies with intensity, toxicity. taxanes such as docetaxel. 0250-7005/2013 $2.00+.40 5655 ANTICANCER RESEARCH 33: 5655-5662 (2013) In our daily practice, docetaxel appears to be less well- To prevent docetaxel-related hypersensitivity or fluid retention, the tolerated in obese patients, but to date, no study has evaluated patients received pre-medication with six doses of corticosteroids the safety of this drug in obese patients. The aim of this (equivalent to 50 mg of prednisolone) starting at 12 h before and ending at 24 h after docetaxel infusion. retrospective study was to assess the toxicities of adjuvant During epirubicin and docetaxel infusion, the patients wore a chemotherapy for early breast cancer in obese patients. We frozen helmet to reduce the risk of alopecia, and during docetaxel also analyzed the potential for using body composition in the infusion, the patients wore frozen gloves to reduce the risk of ungual prediction of chemotherapy toxicity. toxicity. Patients and Methods Toxicity evaluation. At baseline and at the end of the chemotherapy, a complete biological assessment was carried out, including evaluation of liver function, renal function and albumin level. 2 Study population. Every obese patient (BMI ≥30 mg/m ) who The tolerance to chemotherapy was evaluated before each cycle. received adjuvant or neoadjuvant sequential chemotherapy for early A clinical examination and a complete blood count were performed breast cancer between 1 January 2008 and 31 December 2010 at the before each cycle. The haematological toxicities were evaluated from Henri Becquerel Center (France) was included. For comparison, the the complete blood count performed systematically the day before 2 same number of non-obese patients (BMI <30 kg/m ) treated chemotherapy or in the case of fever, and were graded according to identically was randomly chosen from among all non-obese patients the national cancer institute common terminology criteria for adverse treated over the same period. The data on co-morbidities were events (NCI CTCAE) version 4.0 (17). The cardiac toxicity was collected (arterial hypertension, diabetes, cardiac diseases, respiratory monitored by radioisotopic methods or by echocardiogram at baseline insufficiency, and venous thromboembolism). and every two cycles of FEC 100. This retrospective study was approved by our Institutional Non-haematological toxicities were not systematically determined Scientific and Ethic Committees, in accordance with the Declaration because of the risk of bias in the evaluation of such toxicities when of Helsinki. assessed retrospectively. Nevertheless, the type of toxicity that led to a reduced dose intensity of chemotherapy was determined. Tumour evaluation. The tumors were staged according to the Information on unplanned hospitalisations was also collected. Seventh TNM classification (2009) (13). A diagnosis of breast cancer was histologically-verified for each patient after breast Dose intensity evaluation. All events modifying the dose intensity biopsy or surgical excision. The tumours were considered hormone- were collected, i.e. dose reductions, delayed chemotherapy, changes in dependent if hormone receptors were present in more than 10% of regimen or chemotherapy disruptions. the tumor cells. The tumours were considered human epidermal The dose intensity was evaluated by calculating the relative dose growth factor receptor 2 (HER2) positive if the immunochemistry intensity (RDI) (18). RDI=Received dose intensity (mg/m2/week) / score was +++ or if HER2 was amplified by chromogenic in situ planned dose intensity (mg/m2/week) for each drug. These data were hybridization (CISH). collected from our centralized database. The reason for reductions of the dose intensity were also recorded. Chemotherapy. All patients were planned to receive a sequential chemotherapy of three cycles of FEC 100 (5-fluorouracil at 500 Body composition evaluation. Since mid-2009, computed mg/m2, epirubicin at 100 mg/m2, and cyclophosphamide at 500 tomographic (CT) scanning is routinely performed at our Institution mg/m2) followed by three cycles of docetaxel (100 mg/m2) when after a diagnosis of invasive breast carcinoma. When available, the treated with adjuvant chemotherapy and three to four cycles of FEC analysis of body composition was performed with this initial staging 100 followed by three to four cycles of docetaxel when treated with CT scan and was performed on a cross-section centered on the third neoadjuvant chemotherapy. The chemotherapy was administered lumbar vertebra (L3) using dedicated LITIS EA 4108 software intravenously every 21 days. developed in our laboratory. This software was developed to allow for The chemotherapy doses were calculated based on BSA, using the automatic contouring of muscles and fat (sub-cutaneous and visceral) Dubois formula with the actual body weight: BSA (m2)=0.007184 × based on specific Hounsfield units (HU) for each tissue: −29 to 150 height (cm)0.725 × weight (kg)0.425. The BSA was limited to 2 m2, as HU for muscle, −190 to −30 HU for sub cutaneous fat and −150 to is standard at our Institution. −50 HU for visceral fat (19). This automatic contouring was manually In cases of excessive toxicity, treatment
Load more

Recommended publications
  • Package 'Physiology'
    Package ‘physiology’ November 28, 2018 Title Calculate physiologic characteristics of awake and anesthetized adults, children and infants Version 1.2.1 Description A variety of formulae are provided for estimation of physiologic characteristics of infants, children, and adults. Calculations include: body surface area, ideal weight, airway dead-space, the alveolar gas equation, and GFR. Each formula is referenced to the original publication. Future functions will cover more material with a focus on anaesthesia, critical care and peri-operative medicine. License GPL-3 URL https://jackwasey.github.io/physiology/ BugReports https://github.com/jackwasey/physiology/issues Depends R (>= 3.4) Imports Rcpp Suggests childsds, dplyr, ggplot2, lintr, magrittr, rmarkdown, testthat, knitr, spelling, tidyr, utils LinkingTo Rcpp VignetteBuilder knitr Encoding UTF-8 Language en-US LazyData true LazyDataCompression xz RoxygenNote 6.1.1 NeedsCompilation yes Author Jack O. Wasey [aut, cre, cph] (<https://orcid.org/0000-0003-3738-4637>), Bill Denney [ctb] (<https://orcid.org/0000-0002-5759-428X>) Maintainer Jack O. Wasey <[email protected]> Repository CRAN Date/Publication 2018-11-28 22:51:22 UTC 1 2 physiology-package R topics documented: physiology-package . .2 adj_weight_adult . .3 age_from_dates . .3 age_m_to_y . .4 alveolar_PAO2_mmHg . .5 blood_vol_Nadler . .6 bmi_adult . .7 bsa..............................................8 creatinine_mgdl_to_uM . 10 deadspace_equipment_ml . 10 deadspace_total . 11 egfr ............................................. 13 ett_size_by_age . 16 ett_vol_ml . 17 french_to_diameter_mm . 17 henderson_hasselbalch . 18 ideal_weight . 19 ideal_weight_Traub . 20 is_adult . 21 Pa_to_torr . 21 pres_atm_kPa . 22 svp_sea_level . 23 temp_c_to_k . 23 valid_height . 24 Index 26 physiology-package physiology Description A variety of formulae are provided for estimation of physiologic characteristics of infants, children, and adults. Calculations include: body surface area, ideal weight, airway dead-space, the alveolar gas equation, and GFR.
    [Show full text]
  • Standardization and Scoring of the Body Surface Area (BSA) Formulas
    cccceeeerrrr SSSS cccciiiieeennnn aaaannnn cccceeee CCCC &&&& ffff oooo TTTT llll hhhh aaaa eeee Saganuwan and Ndakotsu, J Cancer Sci Ther 2015, 7:1 nnnn rrrr aaa a Journal ofofJournal rrrr p ppp u uuu y yyy o ooo JJJ J DOI: 10.4172/1948-5956.1000319 ISSN: 1948-5956 CancerCancerCancerCancer Science & TherapyTherapyTherapyTherapy Research Article Open Access Standardization and Scoring of the Body Surface Area (BSA) Formulas for Calculation of the Doses of Anticancer Agents for Cancer Patients from the North-Western Nigeria Saganuwan Alhaji Saganuwan1* and Alhaji Muhammadu Ndakotsu2 1Department of Veterinary Physiology, Pharmacology and Biochemistry, College of Veterinary Medicine, University of Agriculture, Nigeria 2Department of Medical Microbiology and Pathology, College of Health Sciences, Usmanu Danfodiyo University, Nigera Abstract Background: Allometric scaling is an empirical examination of the relationship between the pharmacokinetic parameters and body size. Because of the importance of body surface area formulas for calculation of anticancer agents, there is need to standardize and score all the existing body surface area formulas with a view to obtaining the best and most efficient formula that can be adopted for use by our hospitals. Methods: A total of 33 (10.3%) out of 319 presented to the Haematology Department of Usmanu Danfodiyo University Sokoto, Nigeria were diagnosed of Leukaemia and lymphoma. Cyclophosphamide, daunorubicin, vincristine, adriamyin and chlorambucil were used for the treatments. Eleven (11) of the affected 33 patients were randomly selected for calculation of their body surface areas using the formulas of DuBois, Boyd, Gehan and George, Haycock et al., Monsteller, Wang et al., Takashira and Fujimoto. The mean of the results obtained from each formula and for each individual was calculated and compared with all the results provided by the respective formulas and all the formulas scored.
    [Show full text]
  • Cyclophosphamide Exposure Assessed with the Biomarker Phosphoramide Mustard‑Hemoglobin in Breast Cancer Patients: the Tailordose I Study S
    www.nature.com/scientificreports OPEN Cyclophosphamide exposure assessed with the biomarker phosphoramide mustard‑hemoglobin in breast cancer patients: The TailorDose I study S. A. M. Gernaat1*, H. von Stedingk2, M. Hassan3, H. P. Nilsson4, K. A. Rodriguez‑Wallberg5,6, E. Hedayati5,7,8 & P. Rydberg5,8 Cyclophosphamide (CPA) dosing by body surface area (BSA, m2) has been questioned as a predictor for individual drug exposure. This study investigated phosphoramide mustard‑hemoglobin (PAM‑Hb, pmol g−1 Hb) as a biomarker of CPA exposure in 135 female breast cancer patients receiving CPA during three courses based on BSA: 500 mg/m2 (C500 group, n = 67) or 600 mg/m2 (C600 group, n = 68). The inter‑individual diference was calculated for both groups by dividing the highest through the lowest PAM‑Hb value of each course. The inter‑occasion diference was calculated in percentage for each individual by dividing their PAM‑Hb value through the group mean per course, and subsequently dividing this ratio of the latter through the previous course. A multivariable linear regression (MLR) was performed to identify factors that explained the variation of PAM‑Hb. During the three courses, the inter‑individual diference changed from 3.5 to 2.1 and the inter‑occasion diference ranged between 13.3% and 11.9% in the C500 group. In the C600 group, the inter‑individual diference changed from 2.7 to 2.9 and the inter‑occasion diference ranged between 14.1% and 11.7%. The MLR including BSA, age, GFR, and albumin explained 17.1% of the variation of PAM‑Hb and was signifcantly better then the model including only BSA.
    [Show full text]
  • The Influence of Body Composition on the Systemic Exposure Of
    pharmaceuticals Article The Influence of Body Composition on the Systemic Exposure of Paclitaxel in Esophageal Cancer Patients Leni van Doorn 1,* , Marie-Rose B. S. Crombag 2 ,Hánah N. Rier 3, Jeroen L. A. van Vugt 4, Charlotte van Kesteren 5 , Sander Bins 1, Ron H. J. Mathijssen 1 , Mark-David Levin 3 and Stijn L. W. Koolen 1,2 1 Department of Medical Oncology, Erasmus MC Cancer Institute, 3015 GD Rotterdam, The Netherlands; [email protected] (S.B.); [email protected] (R.H.J.M.); [email protected] (S.L.W.K.) 2 Department of Hospital Pharmacy, Erasmus MC, University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands; [email protected] 3 Department of Internal Medicine, Albert Schweitzer Hospital, 3318 AT Dordrecht, The Netherlands; [email protected] (H.N.R.); [email protected] (M.-D.L.) 4 Department of Surgery, Erasmus MC University Medical Center Rotterdam, 3015 GD Rotterdam, The Netherlands; [email protected] 5 Department of Pharmacy, Albert Schweitzer Hospital, 3318 AT Dordrecht, The Netherlands; [email protected] * Correspondence: [email protected] Abstract: Changes in body composition are associated with chemotherapy-related toxicities and effectiveness of treatment. It is hypothesized that the pharmacokinetics (PK) of chemotherapeutics may depend on body composition. The effects of body composition on the variability of paclitaxel PK were studied in patients with esophageal cancer. Skeletal muscle index (SMI), visceral adipose tissue (VAT), and skeletal muscle density (SMD) were measured at the third lumbar vertebra on computed tomography (CT) scans performed before treatment.
    [Show full text]
  • Body Surface Area Capping May Not Improve Cytotoxic Drugs Tolerance
    www.nature.com/scientificreports OPEN Body surface area capping may not improve cytotoxic drugs tolerance Wafa Bouleftour1*, Agathe Viard2, Benoite Mery1, Robin Chaux3, Nicolas Magne4, Xavier Simoens2, Romain Rivoirard1 & Fabien Forges2 Capping body surface area (BSA) at 2 m2 is a routine clinical practice. It aims at reducing toxicities in over 2 m2 BSA patients. 455,502 computerized chemotherapy prescriptions made between 2011 and 2017 were taken from BPC software. Chemotherapy computerized order entry is created by a senior physician prescribers before patient consultation. Only prescriptions with dose calculation involving BSA were selected. 51,179 chemotherapy prescriptions were analyzed; corresponding to 7206 patients who received intravenous chemotherapy. The number of chemotherapy prescriptions in over 2 m2 BSA patients was nearly the same in the hematology as in the oncology departments. But, 79.1% of prescriptions were capped at 2 m2 in the oncology department contrary to 21.9% in the hematology department. Practices analysis showed more dose limitation in palliative situations in both departments. Unexpectedly, 6.53% of capped prescriptions were performed in patients with normal BMI. The patients who received capped doses of chemotherapy had neither fewer dose reductions due to toxicity nor deterioration of their general condition. Capping did not induce fewer dose reductions in patients with BSA greater than 2 m2. Prospective studies in this population are needed to standardize chemotherapy administration in population with BSA > 2 m2. What characterizes injectable anticancer drugs is their narrow therapeutic index, posology liked with dose intensity and signifcant variable non-specifc toxic efects. In an attempt to maximize anti-tumor efects associ- ated with a good tolerance of treatment and acceptable levels of toxicity, drugs prescriptions were based on body surface area (BSA).
    [Show full text]
  • Association Between Body Surface Area and Outcomes After Percutaneous Coronary Intervention
    Journal of Patient-Centered Research and Reviews Volume 2 Issue 1 Article 3 1-30-2015 Association Between Body Surface Area and Outcomes After Percutaneous Coronary Intervention Kambiz Shetabi Tonga Nfor Fengyi Shen Anjan Gupta Tanvir Bajwa Suhail Allaqaband Follow this and additional works at: https://aurora.org/jpcrr Part of the Cardiology Commons, Cardiovascular Diseases Commons, Cardiovascular System Commons, and the Medical Anatomy Commons Recommended Citation Shetabi K, Nfor T, Shen F, Gupta A, Bajwa T, Allaqaband S. Association between body surface area and outcomes after percutaneous coronary intervention. J Patient Cent Res Rev. 2015;2:9-16. doi: 10.17294/ 2330-0698.1048 Published quarterly by Midwest-based health system Advocate Aurora Health and indexed in PubMed Central, the Journal of Patient-Centered Research and Reviews (JPCRR) is an open access, peer-reviewed medical journal focused on disseminating scholarly works devoted to improving patient-centered care practices, health outcomes, and the patient experience. Association Between Body Surface Area and Outcomes After Percutaneous Coronary Intervention *Kambiz Shetabi, MD, *Tonga Nfor, MD, MSPH, Fengyi Shen, MD, Anjan Gupta, MD, Tanvir Bajwa, MD, Suhail Allaqaband, MD Aurora Cardiovascular Services, Aurora Sinai/Aurora St. Luke’s Medical Centers, University of Wisconsin School of Medicine and Public Health, Milwaukee, WI Purpose Obesity is a well-known risk factor for adverse cardiovascular events, but some studies suggest higher body mass index (BMI) is associated with better outcomes after ST-segment elevation myocardial infarction (STEMI). We sought to determine the effect of body surface area (BSA) on adverse events after primary percutaneous coronary intervention (PCI) for STEMI and how this relates to the reported obesity paradox theory.
    [Show full text]
  • Appropriate Chemotherapy Dosing for Obese Adult Patients with Cancer: American Society of Clinical Oncology Clinical Practice Guideline
    Appropriate Chemotherapy Dosing for Obese Adult Patients with Cancer: American Society of Clinical Oncology Clinical Practice Guideline Table of Contents Data Supplement 1 - Evidence Table Data Supplement 2- Evidence Table: Pharmacokinetic Studies Data Supplement 3: Search strategy Data Supplement 4: Quorom Diagram Data Supplement 5: Glossary and BSA Formulas Data Supplement 6: Interpretation of BMI for adults 1 Data Supplement 1 - Evidence Table Author, Year Objectives Methods Efficacy Toxicities Conclusions Lyman, 2003 To assess practice patterns in Review BMI as a measure of obesity was associated with increasing reductions in RDI. Patients with high BMI or BSA of 2 m2 or greater also experienced Multivariate analysis identified several independent predictors for reduced adjuvant chemotherapy for greater reductions in dose-intensity. RDI, including increased age; chemotherapy with CMF, AC, CAF; a 28-day ESBC and to define the Chemotherapy The association between BMI based on WHO criteria and RDI was related to a reduction in schedule; BSA > than 2 m2; and no primary CSF prophylaxis. incidence and predictive AC, CMF, CAF, planned dose-intensity. Most of the difference in RDI observed with increasing obesity was in factors of RDI planned dose, with virtually no difference in the need for unplanned N= 1,243 community oncology practices surveyed nationwide; data extracted Dose reductions ≥ 15% occurred in 36.5% of patients, and there were treatment delays ≥7 days dose modifications owing to toxicity. Therefore, there seems to be a from records of 20,799 ESBC patients treated with adjuvant chemotherapy in 24.9% of patients, resulting in 55.5% of patients receiving RDI less than 85%.
    [Show full text]